This will be one of the important issues for the new Minister of Health when closing the Social Security budget: how to promote the increase in the penetration of biosimilars (generic versions of biological drugs) in France in order to generate more savings.
Penetration stagnated at 32%, with significant differences between the hospital (nearly 90%) and the city (23%), and depending on the molecules (less than 20% for insulin).
We are far from the target of 80% which had been set in 2018 by the former Minister of Health, Agnès Buzyn, and from the European average of 55%.
Because the list of biosimilar drugs available in France is still limited.
They are only 16, of which 9 are prescribed mainly in town.
Out of a total market of biological drugs of 4 billion euros, only a third is biosimilarizable (1.4 billion).
But the stakes are high.
Because they are around 30% cheaper, biosimilars represent an important pool…
This article is for subscribers only.
You have 71% left to discover.
Cultivating your freedom is cultivating your curiosity.
Keep reading your article for €0.99 for the first month
I ENJOY IT
Already subscribed?
Login
